Instructor Notes — Chapter 2
Teaching notes
What this chapter is actually for
§2.9. Everything before it is scaffolding for §2.9.
The chapter teaches receptor pharmacology competently, and students need that vocabulary. But the reason it exists is to establish, with enough mechanistic detail that students feel the force of it, that mechanism does not settle outcome questions. If they leave able to draw a GPCR cascade but still reasoning "it activates the receptor, so it works," the chapter has failed.
The most efficient way to prevent that: teach §2.9's seven-step diagram early, on day one of the chapter, and then return to it repeatedly. It reframes everything that comes before as "these are steps 1 through 5."
Common misconceptions
"The peptide goes into the cell and does something." Very common, and it survives a first explanation. Students picture a delivery. The correction that works: the peptide never enters, and the cell does all the work using its own energy — which is why the cell type determines the effect, not the peptide. Ask what happens if a cell has the receptor but lacks the downstream machinery. The answer (nothing) usually produces the click.
"More binding = more effect." Conflates affinity with efficacy. §2.6 addresses it directly and exercise 2.15 catches it. Worth spending real time on, because the affinity-quoting marketing claim is the single most common one students will encounter in the wild.
"Tolerance means the drug is bad." No — tolerance is predictable from the physiology, and the useful question is which kind of system you are acting on. The §2.8 rule (override vs. replace) is the highest-value transferable content in the chapter and students grasp it fast once it is stated as a rule rather than a list of examples.
"If we understand the mechanism we can predict what will happen." The chapter's target misconception. Case Study 1's beta-blocker detail is the best single counterexample available: the receptor was fully characterized, the mechanistic prediction was that beta-blockade would be harmful in heart failure, and the trials showed the opposite. Fully understood mechanism, wrong prediction.
The overcorrection, which appears in strong students by the end: "mechanism doesn't matter." Catch it. §2.9's final subsection exists for this, and exercise 2.26 explicitly asks for the best counterargument. A student who cannot articulate what mechanism is good for has swapped one error for another.
The hardest point to teach
Why mechanism is asymmetric — strong evidence against, weak evidence for.
Students accept "mechanism isn't proof" easily and then apply it symmetrically, concluding that mechanistic reasoning is always weak. That is wrong and it costs them the most useful tool in Chapter 1.
The framing that works: a chain with seven links. To conclude the chain works, all seven must hold — and you have evidence for one. To conclude it fails, you need only demonstrate that one link is broken. That is why "an unmodified peptide cannot survive digestion intact" is nearly decisive, while "it activates the receptor" is nearly worthless. Same kind of reasoning, opposite strength, and the asymmetry comes from the logic of conjunction rather than from anything about biology.
Draw the chain. Cross out one link. Ask what you now know. Then restore it and cross out nothing, and ask the same question.
Demonstrations that work
The amplification chain, physically. One student is the peptide. They tap one person (the receptor). That person taps three (G proteins). Each of those taps three. By the fourth round the whole room is standing. Then ask: how many peptides were needed? One. It takes ninety seconds and students remember picomolar concentrations afterward.
The partial agonist demo. Two volunteers at a doorway. Full agonist opens the door fully; partial agonist opens it 40%. Alone, the partial agonist is opening the door — an activator. Now have them compete for the doorway: every time the partial agonist gets there first, the door is only 40% open. Average opening drops. Same person, opposite role. This is the single most confusing item in the chapter and this demo resolves it in two minutes.
Reading a real label. Pull up the oliceridine label on DailyMed alongside Case Study 2 and have students find the class warnings. The gap between "designed to be a safer opioid" and the warnings actually on the label lands harder from the primary document than from any summary.
Timing
For a 75-minute session:
| Minutes | Content |
|---|---|
| 0–8 | Draw the seven-step gap first. Tell them the chapter is steps 1–5 and Chapter 5 is steps 6–7. |
| 8–20 | §2.1–2.2 — messaging ranges, induced fit, binding ≠ activating. |
| 20–35 | §2.3–2.4 — the GPCR cascade and the amplification demo. |
| 35–48 | §2.5–2.6 — the five ligand types (partial agonist demo) and the affinity/potency/efficacy distinction. |
| 48–60 | §2.7–2.8 — termination, and the override-vs-replace rule. |
| 60–75 | §2.9 — return to the seven steps. Case Study 2 if time allows; otherwise assign it. |
Assessment notes
Exercises 2.19, 2.23, 2.26, and 2.30 are the discriminating items. 2.26 is the best single question in the set because it asks students to argue against the chapter — a student who can only agree has memorized rather than understood.
Exercise 2.30/2.31 (charting a dossier peptide against the seven steps) is where the chapter becomes personal. Many students discover that a compound they were confident about has evidence for step 1 and assumptions for the rest. Do not soften this in feedback; the discomfort is the learning.